K212095 is an FDA 510(k) clearance for the SurGuard3 Safety Hypodermic Needle. Classified as Needle, Hypodermic, Single Lumen (product code FMI), Class II - Special Controls.
Submitted by Terumo Europe N.V. (Leuven, BE). The FDA issued a Cleared decision on August 22, 2022 after a review of 412 days - an unusually long review period, suggesting complex equivalence evaluation.
This device falls under the General Hospital FDA review panel, regulated under 21 CFR 880.5570 - the FDA general hospital device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind General Hospital submissions.
View all Terumo Europe N.V. devices